Dr Anna Olsson-Brown
Anna Olsson-Brown is a Consultant in Medical Oncology. She specialises in the systemic treatment of skin cancers; sarcoma; immunotherapeutic toxicities, and early phase/translational clinical trials. She is the Clinical Director for the Acute Division at the Clatterbridge Cancer Centre, Liverpool and an Honorary Senior Lecturer at the University of Liverpool.
She has a background in clinical pharmacology and specialises in the management of immunotherapeutic toxicities, melanoma, sarcoma and early phase/ translational clinical trials. She has an interest in acute oncology and supportive care for cancer patients particularly with regards to toxicity of cancer therapies. She was an MRC research fellow completing her PhD investigating the mechanisms of immunotherapy toxicity and has subsequently published extensively in the area.
She established and leads a pan-tumour, pan-regional immunotherapy toxicity service supporting inpatients and outpatients with immunotherapy toxicities. She is the current immunotherapy toxicity work stream lead for the NIHR Oncology Translational Research Committee (O-TRC) and a board member of UKASC. She is a founding member and current CEO of the National Immunotherapy Clinical Network (IOCN) and sits on the UK Chemotherapy Board within this role. Within Clatterbridge she is the Chair of the Immunotherapy Committee and Deputy Chair of Supportive Care SRG.
She is a current Clinical Advisor to Health Education England and the British Medical Journal, Oncology representative of the Symposium Committee at the Royal College of Physicians of Edinburgh, representative on the Association of Cancer Physicians and RCPE new consultant committees and senior advisor to the National Oncology Collaboration for Trainee Research (NOTCH).